In the News Details

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published in Cell Reports by Gai Ayalon et al.

 Please read and watch the videos “It takes Tau to Tangle” here.

 AC Immune and Genentech have been partners for a decade:

• In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.
• In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies.

 You can find out more about our collaborations on our Partners page.